MICHELETTO, CLAUDIO
 Distribuzione geografica
Continente #
EU - Europa 2.272
NA - Nord America 1.792
AS - Asia 1.373
SA - Sud America 187
AF - Africa 46
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.674
Nazione #
US - Stati Uniti d'America 1.744
RU - Federazione Russa 945
SG - Singapore 594
CN - Cina 392
GB - Regno Unito 380
IT - Italia 362
BR - Brasile 156
HK - Hong Kong 131
DE - Germania 111
SE - Svezia 102
FR - Francia 98
VN - Vietnam 79
IE - Irlanda 76
FI - Finlandia 62
PL - Polonia 43
KR - Corea 42
JP - Giappone 31
CA - Canada 28
IN - India 28
ZA - Sudafrica 21
ID - Indonesia 17
MX - Messico 17
UA - Ucraina 17
ES - Italia 13
BE - Belgio 12
NL - Olanda 12
AR - Argentina 11
TR - Turchia 11
LT - Lituania 10
AT - Austria 8
MY - Malesia 8
SA - Arabia Saudita 7
BJ - Benin 6
EC - Ecuador 6
PY - Paraguay 6
TG - Togo 6
AE - Emirati Arabi Uniti 5
AZ - Azerbaigian 5
BD - Bangladesh 5
TN - Tunisia 5
CZ - Repubblica Ceca 4
PK - Pakistan 4
CH - Svizzera 3
IL - Israele 3
IQ - Iraq 3
MA - Marocco 3
PE - Perù 3
AU - Australia 2
BG - Bulgaria 2
CL - Cile 2
DO - Repubblica Dominicana 2
HU - Ungheria 2
LB - Libano 2
LV - Lettonia 2
RO - Romania 2
UZ - Uzbekistan 2
VE - Venezuela 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BA - Bosnia-Erzegovina 1
BY - Bielorussia 1
CO - Colombia 1
DK - Danimarca 1
DM - Dominica 1
EG - Egitto 1
GH - Ghana 1
HR - Croazia 1
JO - Giordania 1
KE - Kenya 1
LK - Sri Lanka 1
MZ - Mozambico 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
OM - Oman 1
SN - Senegal 1
Totale 5.674
Città #
Moscow 364
Southend 280
Singapore 279
Chandler 226
Dallas 201
Ashburn 197
Hong Kong 128
Jacksonville 125
Beijing 80
Dublin 76
Verona 73
Redmond 69
Ann Arbor 59
New York 56
Houston 51
The Dalles 45
Milan 43
Los Angeles 41
Woodbridge 41
Munich 35
Lawrence 32
Princeton 32
Boardman 28
Ho Chi Minh City 25
Jinan 25
Tokyo 25
Wilmington 25
Rome 24
São Paulo 23
Helsinki 22
Sindelfingen 21
Buffalo 19
Warsaw 19
Changsha 18
London 18
Bologna 17
Columbus 17
Nanjing 16
Shenyang 16
Tianjin 16
Jakarta 14
Redondo Beach 14
Seattle 14
Hanoi 13
Naples 13
Ningbo 13
Taizhou 13
Toronto 13
Zhengzhou 12
Chennai 11
Denver 11
Turku 11
Atlanta 10
Brussels 10
Johannesburg 10
Phoenix 10
Pretoria 10
Brooklyn 9
Frankfurt am Main 9
Hebei 9
Poplar 9
Council Bluffs 8
Falls Church 8
Haikou 8
Lanzhou 8
Mexico City 8
Santa Clara 8
Turin 8
Chicago 7
Da Nang 7
Kuala Lumpur 7
Manchester 7
Nuremberg 7
San Francisco 7
Taiyuan 7
Ankara 6
Brescia 6
City of Westminster 6
Cotonou 6
Fuzhou 6
Guangzhou 6
Jiaxing 6
Kent 6
Lancaster 6
Lomé 6
Orem 6
Rio de Janeiro 6
Auburn Hills 5
Baku 5
Hangzhou 5
Montreal 5
Norwalk 5
Palermo 5
Redwood City 5
Salvador 5
Ancona 4
Bolzano 4
Boydton 4
Brno 4
Delhi 4
Totale 3.382
Nome #
Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management 388
Cost analysis of GER-induced asthma: a controlled study vs. atopic asthma of comparable severity. 315
Assessment of COVID-19 progression on day 5 from symptoms onset 189
A two-stage logistic Model Based on the Measurament of Pro-Infectious Cytokines in Bronchial Secretions for Assessing Bacterial, Viral and Non-Infectious Origin of COPD Exacerbation - Original Research 180
Diagnostic management of occult nodal lymphangioleiomyomatosis detected during pelvic cancer staging. Localized finding or systemic disease? 176
A MCh test pre-post esophageal acidification in detecting GER-related asthma. 170
Asthmatic patients in COVID-19 outbreak: Few cases despite many cases 166
Long-Term Patient-Centred Follow-up in a Prospective Cohort of Patients with COVID-19 166
Exercise prehabilitation in lung cancer: Getting stronger to recover faster 151
Changes in total IgE plasma concentration measured at the third month during anti-IgE treatment predict future exacerbation rates in difficult-to-treat atopic asthma: a pilot study. 149
Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity 147
Effects of HFA- and CFC-beclomethasone dipropionate on the bronchial response to methacholine (MCh) in mild asthma. 145
Determinants of Persistence of Symptoms and Impact on Physical and Mental Wellbeing in Long COVID: A Prospective Cohort Study 145
How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center 144
Integrating supportive care into the multidisciplinary management of lung cancer: we can't wait any longer 143
Effect of HFA- and CFC-beclomethasone dipropionate on the bronchial response to methacholine (MCh) in mild asthma 138
COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey 135
Molecular predictors of EGFR-mutant NSCLC transformation into LCNEC after frontline osimertinib: digging under the surface 125
Antimicrobial Stewardship in COVID-19 Patients: Those Who Sow Will Reap Even through Hard Times 124
Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase 124
Low‑dose anti‑IL 5 treatment in idiopathic hypereosinophilic syndrome: towards a precision medicine approach for remission maintenance 123
Lung metastasis from TTF-1 positive sigmoid adenocarcinoma. pitfalls and management. 122
A Framework For Step Down Or Therapeutic Re-Organization For Withdrawal Of Inhaled Corticosteroids In Selected Patients With COPD: A Proposal For COPD Management 122
PATTERN OF AIRWAY INFLAMMATION AND REMODELLING IN MILD PERSISTENT ATOPIC ASTHMA AND IN MILD PERSISTENT ASTHMA RELATED TO GASTROESOPHAGEAL REFLUX 115
Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response 114
Reference urinary LTE4 levels in normal individuals: a pilot study. 111
PIKO-1, an effective, handy device for the patient's personal PEFR and FEV1 electronic long-term monitoring. 110
Idiopathic hypereosinophilic syndromes and rare dysimmune conditions associated with hyper-eosinophilia in practice: An innovative multidisciplinary approach 109
Low adherence to inhaled corticosteroids/long-acting β2-agonists and biologic treatment in severe asthmatics 103
Nasal and bronchial tolerability of Rofecoxib in patients with aspirin induced asthma. 101
Multidisciplinary management in type 2 inflammatory disease 100
Omalizumab management beyond clinical trials: the added value of a network model 98
Vitamin D and disease severity in coronavirus disease 19 (COVID-19) 95
Profiling blood hypereosinophilia in patients on dupilumab treatment for respiratory conditions: a real-life snapshot 94
ARIA-ITALY multidisciplinary consensus on nasal polyposis and biological treatments 88
CT radiomic models to distinguish COVID-19 pneumonia from other interstitial pneumonias 86
Nasal and Bronchial Tolerability of Rofecoxib in Patients with Aspirin induced Asthma 86
Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence 82
Dupilumab Efficacy on Asthma Functional, Inflammatory, and Patient-Reported Outcomes across Different Disease Phenotypes and Severity: A Real-Life Perspective 79
Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study 77
Pneumonic versus Nonpneumonic Exacerbations of Chronic Obstructive Pulmonary Disease 76
Reply to "Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis in remission: What is the right dose?" 70
Prevalence of asymptomatic SARS-CoV-2-positive individuals in the general population of northern Italy and evaluation of a diagnostic serological ELISA test: a cross-sectional study protocol 64
Organization, Clinical and Management Indicators on the First Year of Activity of an Outpatient Clinic Dedicated to the Diagnosis and Treatment of Severe Asthma in Italy 53
Long-Term Eosinophil Depletion: A Real-World Perspective on the Safety and Durability of Benralizumab Treatment in Severe Eosinophilic Asthma 45
Totale 5.743
Categoria #
all - tutte 19.040
article - articoli 19.040
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.080


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021136 0 0 0 0 0 31 19 12 20 19 29 6
2021/2022366 52 113 12 22 8 9 5 22 13 8 25 77
2022/2023628 39 71 56 110 64 120 7 33 73 6 30 19
2023/2024497 27 38 47 47 45 78 26 36 12 28 77 36
2024/20251.158 78 59 48 158 50 48 83 82 185 78 101 188
2025/20262.195 197 149 195 552 902 200 0 0 0 0 0 0
Totale 5.743